Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients
Identifieur interne : 001F18 ( Main/Exploration ); précédent : 001F17; suivant : 001F19Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients
Auteurs : I. A. Prescott [Canada] ; J. O. Dostrovsky [Canada] ; E. Moro [Canada] ; M. Hodaie [Canada] ; A. M. Lozano [Canada] ; W. D. Hutchison [Canada]Source :
- Brain [ 0006-8950 ] ; 2009-02.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Basal Ganglia (physiopathology), Basal ganglion, Deep Brain Stimulation, Evoked Potentials (drug effects), Female, Human, Humans, Levodopa, Levodopa (therapeutic use), Locus niger, Male, Microelectrode, Microelectrodes, Middle Aged, Nervous system diseases, Neuronal Plasticity (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (therapy), Parkinson disease, Stimulation, Chemical, Substantia Nigra (drug effects), Substantia Nigra (metabolism), Substantia Nigra (physiopathology), Synaptic plasticity.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug effects : Evoked Potentials, Neuronal Plasticity, Substantia Nigra.
- drug therapy : Parkinson Disease.
- metabolism : Substantia Nigra.
- physiopathology : Basal Ganglia, Parkinson Disease, Substantia Nigra.
- therapy : Parkinson Disease.
- Adult, Aged, Deep Brain Stimulation, Female, Humans, Male, Microelectrodes, Middle Aged, Stimulation, Chemical.
Abstract
Parkinson's disease, caused by the loss of dopaminergic nigrostriatal projections, is a debilitating neurodegenerative disease characterized by bradykinesia, rigidity, tremor and postural instability. The dopamine precursor levodopa (l-dopa) is the most effective treatment for the amelioration of Parkinson's disease signs and symptoms, but long-term administration can lead to disabling motor fluctuations and l-dopa -induced dyskinesias (LIDs). Studies in rat striatal slices have shown dopamine to be an essential component of activity-dependent synaptic plasticity at the input to the basal ganglia, but dopamine is also released from ventrally projecting dendrites of the substantia nigra pars compacta (SNc) on the substantia nigra pars reticulata (SNr), a major output structure of the basal ganglia. We characterized synaptic plasticity in the SNr using field potentials evoked with a nearby microelectrode (fEPs), in 18 Parkinson's disease patients undergoing implantation of deep brain stimulating (DBS) electrodes in the subthalamic nucleus (STN). High frequency stimulation (HFS—four trains of 2 s at 100 Hz) in the SNr failed to induce a lasting change in test fEPs (1 Hz) amplitudes in patients OFF medication (decayed to baseline by 160 s). Following oral l-dopa administration, HFS induced a potentiation of the fEP amplitudes (+29.3% of baseline at 160 s following a plateau). Our findings suggest that extrastriatal dopamine modulates activity-dependent synaptic plasticity at basal ganglia output neurons. Dopamine medication state clearly impacts fEP amplitude, and the lasting nature of the increase is reminiscent of LTP-like changes, indicating that aberrant synaptic plasticity may play a role in the pathophysiology of Parkinson's disease.
Url:
DOI: 10.1093/brain/awn322
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001643
- to stream Istex, to step Curation: 001643
- to stream Istex, to step Checkpoint: 000694
- to stream PubMed, to step Corpus: 000F00
- to stream PubMed, to step Curation: 000F00
- to stream PubMed, to step Checkpoint: 000F00
- to stream Ncbi, to step Merge: 000996
- to stream Ncbi, to step Curation: 000996
- to stream Ncbi, to step Checkpoint: 000996
- to stream Main, to step Merge: 002071
- to stream PascalFrancis, to step Corpus: 000573
- to stream PascalFrancis, to step Curation: 000719
- to stream PascalFrancis, to step Checkpoint: 000446
- to stream Main, to step Merge: 002250
- to stream Main, to step Curation: 001F18
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients</title><author><name sortKey="Prescott, I A" sort="Prescott, I A" uniqKey="Prescott I" first="I. A." last="Prescott">I. A. Prescott</name></author><author><name sortKey="Dostrovsky, J O" sort="Dostrovsky, J O" uniqKey="Dostrovsky J" first="J. O." last="Dostrovsky">J. O. Dostrovsky</name></author><author><name sortKey="Moro, E" sort="Moro, E" uniqKey="Moro E" first="E." last="Moro">E. Moro</name></author><author><name sortKey="Hodaie, M" sort="Hodaie, M" uniqKey="Hodaie M" first="M." last="Hodaie">M. Hodaie</name></author><author><name sortKey="Lozano, A M" sort="Lozano, A M" uniqKey="Lozano A" first="A. M." last="Lozano">A. M. Lozano</name></author><author><name sortKey="Hutchison, W D" sort="Hutchison, W D" uniqKey="Hutchison W" first="W. D." last="Hutchison">W. D. Hutchison</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4324554E8404D80ADB0824159A9CBCF287E45680</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1093/brain/awn322</idno><idno type="url">https://api-v5.istex.fr/document/4324554E8404D80ADB0824159A9CBCF287E45680/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001643</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001643</idno><idno type="wicri:Area/Istex/Curation">001643</idno><idno type="wicri:Area/Istex/Checkpoint">000694</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000694</idno><idno type="wicri:doubleKey">0006-8950:2009:Prescott I:levodopa:enhances:synaptic</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19050033</idno><idno type="wicri:Area/PubMed/Corpus">000F00</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F00</idno><idno type="wicri:Area/PubMed/Curation">000F00</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F00</idno><idno type="wicri:Area/PubMed/Checkpoint">000F00</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F00</idno><idno type="wicri:Area/Ncbi/Merge">000996</idno><idno type="wicri:Area/Ncbi/Curation">000996</idno><idno type="wicri:Area/Ncbi/Checkpoint">000996</idno><idno type="wicri:Area/Main/Merge">002071</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0108581</idno><idno type="wicri:Area/PascalFrancis/Corpus">000573</idno><idno type="wicri:Area/PascalFrancis/Curation">000719</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000446</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000446</idno><idno type="wicri:doubleKey">0006-8950:2009:Prescott I:levodopa:enhances:synaptic</idno><idno type="wicri:Area/Main/Merge">002250</idno><idno type="wicri:Area/Main/Curation">001F18</idno><idno type="wicri:Area/Main/Exploration">001F18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients</title><author><name sortKey="Prescott, I A" sort="Prescott, I A" uniqKey="Prescott I" first="I. A." last="Prescott">I. A. Prescott</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Department of Physiology, University of Toronto, Canada 2 Division of Neurosurgery, Department of Surgery, Toronto Western Research Institute and Krembil Neuroscience Centre</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Dostrovsky, J O" sort="Dostrovsky, J O" uniqKey="Dostrovsky J" first="J. O." last="Dostrovsky">J. O. Dostrovsky</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Department of Physiology, University of Toronto, Canada 2 Division of Neurosurgery, Department of Surgery, Toronto Western Research Institute and Krembil Neuroscience Centre</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Moro, E" sort="Moro, E" uniqKey="Moro E" first="E." last="Moro">E. Moro</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Department of Physiology, University of Toronto, Canada 2 Division of Neurosurgery, Department of Surgery, Toronto Western Research Institute and Krembil Neuroscience Centre</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Hodaie, M" sort="Hodaie, M" uniqKey="Hodaie M" first="M." last="Hodaie">M. Hodaie</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Department of Physiology, University of Toronto, Canada 2 Division of Neurosurgery, Department of Surgery, Toronto Western Research Institute and Krembil Neuroscience Centre</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Lozano, A M" sort="Lozano, A M" uniqKey="Lozano A" first="A. M." last="Lozano">A. M. Lozano</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Department of Physiology, University of Toronto, Canada 2 Division of Neurosurgery, Department of Surgery, Toronto Western Research Institute and Krembil Neuroscience Centre</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Hutchison, W D" sort="Hutchison, W D" uniqKey="Hutchison W" first="W. D." last="Hutchison">W. D. Hutchison</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>1 Department of Physiology, University of Toronto, Canada 2 Division of Neurosurgery, Department of Surgery, Toronto Western Research Institute and Krembil Neuroscience Centre</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Canada</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain</title><idno type="ISSN">0006-8950</idno><idno type="eISSN">1460-2156</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2009-02">2009-02</date><biblScope unit="volume">132</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="309">309</biblScope><biblScope unit="page" to="318">318</biblScope></imprint><idno type="ISSN">0006-8950</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8950</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Basal Ganglia (physiopathology)</term><term>Basal ganglion</term><term>Deep Brain Stimulation</term><term>Evoked Potentials (drug effects)</term><term>Female</term><term>Human</term><term>Humans</term><term>Levodopa</term><term>Levodopa (therapeutic use)</term><term>Locus niger</term><term>Male</term><term>Microelectrode</term><term>Microelectrodes</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Neuronal Plasticity (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (therapy)</term><term>Parkinson disease</term><term>Stimulation, Chemical</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (metabolism)</term><term>Substantia Nigra (physiopathology)</term><term>Synaptic plasticity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Evoked Potentials</term><term>Neuronal Plasticity</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Basal Ganglia</term><term>Parkinson Disease</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Deep Brain Stimulation</term><term>Female</term><term>Humans</term><term>Male</term><term>Microelectrodes</term><term>Middle Aged</term><term>Stimulation, Chemical</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Homme</term><term>Locus niger</term><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Microélectrode</term><term>Noyau gris central</term><term>Pathologie du système nerveux</term><term>Plasticité synaptique</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Parkinson's disease, caused by the loss of dopaminergic nigrostriatal projections, is a debilitating neurodegenerative disease characterized by bradykinesia, rigidity, tremor and postural instability. The dopamine precursor levodopa (l-dopa) is the most effective treatment for the amelioration of Parkinson's disease signs and symptoms, but long-term administration can lead to disabling motor fluctuations and l-dopa -induced dyskinesias (LIDs). Studies in rat striatal slices have shown dopamine to be an essential component of activity-dependent synaptic plasticity at the input to the basal ganglia, but dopamine is also released from ventrally projecting dendrites of the substantia nigra pars compacta (SNc) on the substantia nigra pars reticulata (SNr), a major output structure of the basal ganglia. We characterized synaptic plasticity in the SNr using field potentials evoked with a nearby microelectrode (fEPs), in 18 Parkinson's disease patients undergoing implantation of deep brain stimulating (DBS) electrodes in the subthalamic nucleus (STN). High frequency stimulation (HFS—four trains of 2 s at 100 Hz) in the SNr failed to induce a lasting change in test fEPs (1 Hz) amplitudes in patients OFF medication (decayed to baseline by 160 s). Following oral l-dopa administration, HFS induced a potentiation of the fEP amplitudes (+29.3% of baseline at 160 s following a plateau). Our findings suggest that extrastriatal dopamine modulates activity-dependent synaptic plasticity at basal ganglia output neurons. Dopamine medication state clearly impacts fEP amplitude, and the lasting nature of the increase is reminiscent of LTP-like changes, indicating that aberrant synaptic plasticity may play a role in the pathophysiology of Parkinson's disease.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><region name="Ontario"><name sortKey="Prescott, I A" sort="Prescott, I A" uniqKey="Prescott I" first="I. A." last="Prescott">I. A. Prescott</name></region><name sortKey="Dostrovsky, J O" sort="Dostrovsky, J O" uniqKey="Dostrovsky J" first="J. O." last="Dostrovsky">J. O. Dostrovsky</name><name sortKey="Hodaie, M" sort="Hodaie, M" uniqKey="Hodaie M" first="M." last="Hodaie">M. Hodaie</name><name sortKey="Hutchison, W D" sort="Hutchison, W D" uniqKey="Hutchison W" first="W. D." last="Hutchison">W. D. Hutchison</name><name sortKey="Hutchison, W D" sort="Hutchison, W D" uniqKey="Hutchison W" first="W. D." last="Hutchison">W. D. Hutchison</name><name sortKey="Lozano, A M" sort="Lozano, A M" uniqKey="Lozano A" first="A. M." last="Lozano">A. M. Lozano</name><name sortKey="Moro, E" sort="Moro, E" uniqKey="Moro E" first="E." last="Moro">E. Moro</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:4324554E8404D80ADB0824159A9CBCF287E45680
|texte= Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients
}}
| This area was generated with Dilib version V0.6.29. |  |